Frequently Asked Questions
We address the most commonly asked clinical and technical questions.
Minimally Invasive Diagnostic Device (MIMD)
MIMD relates to an apparatus and method for testing samples, specifically for in vitro testing of blood samples for biomarkers found in cells and tissues. It utilizes proprietary technologies.
MIMD employs a disposable substrate test strip. Sample is placed for detecting changes in morphologies.
Artificial intelligence models are embedded in microprocessors to assess the morphological changes in the samples. These models process data in real-time, allowing for rapid detection of diseases and classification of samples.
The system can provide results in less than 3 minutes in experimental setups. It ensures real-time, rapid analysis of samples.
This system offers early-stage, non-invasive, real-time, point-of-care health diagnosis with minimal computational time and complexity. It provides high accuracy, sensitivity, and specificity in disease detection.
Yes, the system can monitor the progression of diseases by classifying subject samples based on the morphology (Periodic Monitoring is required). It provides valuable insights into disease development.
The system calibrates using known feature-based data, which are compared in real-time against data from the cloud server via IoT interface. Calibration ensures accurate analysis results.
Yes, the system is designed for ease of use and can be utilized by both healthcare professionals and patients. It is minimally-invasive and provides real-time results.
Yes, the system can be integrated into existing healthcare technologies due to its compatibility and adaptability. It can enhance the capabilities of current healthcare systems.
The system can detect and classify various diseases, including neurodegenerative, endocrinology, cardiac, cancers, and more, based on the morphology of metabolic changes.
It is possible that the system can differentiate between disease sub-types based on the unique metabolic changes observed, providing detailed insights into the nature of the disease.
No, the system can analyze a wide range of diseases beyond blood-related ones. It is applicable to diverse medical conditions.
The system's high dimensional characteristic features and AI models enable it to identify complex diseases like cancer by analyzing subtle changes in molecular composition.
While the system provides rapid results, it is primarily designed for point-of-care diagnosis. Continuous monitoring capabilities could be explored in future iterations.
The system offers real-time, accurate, and non-invasive diagnosis, enabling healthcare providers to make informed decisions swiftly. Its high sensitivity and specificity enhance diagnostic accuracy.
The system's technology can potentially be adapted to analyze samples from other bodily fluids, broadening its diagnostic applications.
The system represents the future of healthcare diagnostics by offering real-time, accurate, and non-invasive disease detection.